Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

3.2%

1 terminated out of 31 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (2)
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (1)

Trial Status

Recruiting10
Not Yet Recruiting8
Enrolling By Invitation5
Completed4
Active Not Recruiting3
Terminated1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT06372457Active Not RecruitingPrimary

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT07381894RecruitingPrimary

Multicentre Hypertrophic Cardiomyopathy Registry

NCT07529938CompletedPrimary

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

NCT06599229Active Not RecruitingPrimary

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT07054073RecruitingPrimary

HCMR Re-Imaging Study

NCT07464132Phase 1Recruiting

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

NCT07155434TerminatedPrimary

ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

NCT07454135Not Yet RecruitingPrimary

Mechanisms of Atrial Pathoelectrophysiology in HCM

NCT04219826Phase 2CompletedPrimary

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

NCT07344480RecruitingPrimary

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

NCT07408427Not Yet RecruitingPrimary

Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy

NCT07336290Enrolling By InvitationPrimary

One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance

NCT07359690Recruiting

Multimodal Analysis of Endomyocardial Biopsies

NCT07103655Phase 4Not Yet RecruitingPrimary

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

NCT07354646Recruiting

The Application of T1 Mapping in Real-World

NCT02413450Enrolling By Invitation

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT07332767Not Yet RecruitingPrimary

Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy

NCT07295613Enrolling By InvitationPrimary

ReGistry of hypeRtrophic cArDIomyopathy: Regional fEatures, geNeTics and Course

NCT07263204RecruitingPrimary

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

NCT07202897Phase 3Not Yet RecruitingPrimary

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Scroll to load more

Research Network

Activity Timeline